| Literature DB >> 35897509 |
Kamila Malewska-Kaczmarek1, Katarzyna Bobeff2, Tymoteusz Mańkowski3, Daniela Podlecka1, Joanna Jerzyńska1, Iwona Stelmach4.
Abstract
Exercise may trigger bronchoconstriction, especially in a group of athletes in whom bronchospasm during exercise is reported to occur more frequently than in nonathletes. The aim of this study was to determine the prevalence and environmental risk factors contributing to exercise-induced bronchoconstriction (EIB) in adolescent athletes. A prospective study was conducted among a group of 101 adolescent athletes who underwent spirometry, exercise challenge, fractional exhaled nitric oxide (FeNO) measurements, and allergy assessment. The study group was divided into three subgroups of athletes based on the most common sports environments: swimmers, "indoor" athletes, and "outdoor" athletes. The clinical evaluation demonstrated a high frequency of EIB in the study group. Moreover, a large proportion of the athletes in whom EIB was observed reported no pre-existing symptoms suggestive of bronchospasm or asthma. Among patients without a previous diagnosis of asthma, clinical evaluation confirmed 22% with positive exercise challenges, compared with 77% of adolescents with negative test results. Moreover, among the athletes with a history of asthma, 39% had positive exercise challenges. Both EIB and asthma are common conditions that affect adolescent athletes. Physicians should pay particular attention to this group, as the symptoms can lead to under- and overdiagnosis.Entities:
Keywords: EIB; adolescent athletes; sport
Mesh:
Year: 2022 PMID: 35897509 PMCID: PMC9367722 DOI: 10.3390/ijerph19159119
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Patient characteristics.
| Variables | |
|---|---|
| Age (years), mean ± SD | 13.9 ± 1.7 |
| Female gender, | 39 (38.6) |
| Male gender, | 62 (61.3) |
| Body weight (kg), mean ± SD | 54.9 ± 14.4 |
| Height (cm), mean ± SD | 163.6 ± 16 |
| BMI (kg/m2) *, mean ± SD | 20.1± 2.7 |
| FEV1 (% best/pred.) **, mean ± SD | 106.1 ± 14.4 |
| FVC (% best/pred.) ***, mean ± SD | 105.3 ± 13.6 |
| FeNO (ppb) ****, mean ± SD | 49.3 ± 36 |
* Body mass index; ** forced expiratory volume in 1 s; *** forced vital capacity; **** fractional exhaled nitric oxide.
Distribution of athletes in the study depending on their practiced discipline.
| Variables | ||
|---|---|---|
| Outdoor athletes | Football, | 39 (39) |
| Horse riding, | 3 (3) | |
| Indoor athletes | Tennis, | 2 (2) |
| Dance, | 4 (4) | |
| Athletics, | 4 (4) | |
| Cycling, | 4 (4) | |
| Martial arts, | 8 (7.9) | |
| Gymnastics, | 1 (1) | |
| Floorball, | 1 (1) | |
| Basketball, | 10 (9.9) | |
| Volleyball, | 2 (2) | |
| Handball, | 2 (2) | |
| Swimmers | Swimming, | 21 (21) |
Figure 1Differences between study groups among EIB-positive and EIB-negative patients.
Details concerning EIB-positive and EIB-negative athletes.
| EIB (+) ( | EIB (−) ( |
| |
|---|---|---|---|
| 11 (39%) | 13 (18%) | 0.04455 | |
| 17 (61%) | 60 (82%) | ||
| 21 (75%) | 33 (45%) | 0.00721 | |
| 7 (25%) | 40 (55%) | ||
| 11 (39%) | 11 (15%) | 0.01778 | |
| 15 (54%) | 20 (27%) | 0.02504 | |
| 11 (39%) | 11 (15%) | 0.01778 |
* Inhaled corticosteroids–long-acting beta-agonists.
Figure 2Exercise challenge and treatment in EIB+ and EIB− athletes.
Figure 3Differences between study groups: median, interquartile range (25–75%), and minimum and maximum values: (a) box plot of FEV1 in groups of disciplines depending on the sports environment; (b) box plot of FVC in groups of disciplines depending on sports environment; (c) box plot of FeNO depending on sports environment. * statistically significant result.
Spirometry parameters by athlete groups.
| Outdoor Athletes | Swimmers | Indoor Athletes | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median | 25% | 75% | Median | 25% | 75% | Median | 25% | 75% |
| |
| FEV1 % | 107 | 96 | 115 | 115 | 95 | 125 | 101.5 | 92 | 111 | |
| FEV1/FVC % * | 100 | 91 | 106 | 102 | 96 | 107 | 100.5 | 96 | 106 | |
| PEF % ** | 95 | 86 | 111 | 98 | 92 | 104 | 89 | 81 | 99 | |
| FVC | 104 | 98 | 114 | 110 | 100 | 124 | 99 | 91 | 111 | |
| MEF25 *** | 84 | 68 | 94 | 93 | 74 | 115 | 87 | 65 | 103 | |
| MEF50 *** | 93 | 78 | 110 | 104 | 73 | 115 | 85 | 70 | 103 | |
| MEF75 *** | 100 | 86 | 111 | 99 | 89 | 116 | 94 | 81 | 102 | |
| FeNO | 29 | 22.3 | 46.5 | 35.8 | 28.6 | 60.4 | 48.5 | 29.3 | 72.3 | |
| Resistance % | 144.5 | 127 | 161.5 | 144 | 114 | 180 | 145.5 | 131 | 166 | |
* Forced expiratory volume in one second % of vital capacity; ** peak expiratory flow; *** maximal expiratory flows at 25%, 50%, and 75% of FVC.
Figure 4Athletes with increased FeNO divided by place of training of study groups.